Colorectal cancer is one of the more commonly diagnosed cancers among both men and women today. Despite the fact that it most exclusively affects older persons, colorectal cancer is continuing to be diagnosed in younger and younger patients. CURE Connections wants to answer any questions you might have when it comes to managing colorectal cancer. This program includes information as shared by an expert physician, and personal accounts from patients and their caretakers who have dealt with colorectal cancer.
A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovi (binimetinib), and the EGFR inhibitor Erbitux (cetuximab) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following one or two prior lines of treatment in the metastatic setting.